早期与延迟房颤导管消融对房性心律失常复发的影响
本研究将100例有症状房颤患者随机分为早期消融(招募后1个月内)或延迟消融(优化药物治疗后12个月消融),89例完成方案。12个月无复发率早期组56.3% vs 延迟组58.6%(HR 1.12,95%CI 0.59-2.13,P=0.7),其他次要终点均无显著差异。
要点
- 早期消融与延迟消融在12个月无房性心律失常复发率无显著差异。
- 延迟消融组房颤负荷、抗心律失常药物使用与早期组相当。
- 阵发性与持续性房颤亚组中房颤负荷均无显著组间差异。
核心结论
- 与早期消融策略相比,延迟12个月进行房颤消融以优化药物治疗并未降低消融疗效。
研究设计与样本
- 随机对照试验,100例有症状房颤患者按1:1随机分配至早期消融组(招募后1个月内)或延迟消融组(优化药物治疗后12个月消融)。
- 89例完成研究方案(早期组48例,延迟组41例),平均年龄59±12.9岁,女性占29%,肺静脉隔离成功率100%。
主要发现
- 12个月时早期消融组56.3%无心律失常复发,延迟消融组58.6%无复发(HR 1.12,95%CI 0.59-2.13,P=0.7)。
- 中位房颤负荷早期组0%(IQR 3.2)vs 延迟组0%(IQR 5),P=0.66。
- 阵发性房颤患者中位房颤负荷早期组0%(IQR 1.1)vs 延迟组0%(IQR 4.5),P=0.78。
- 持续性房颤患者中位房颤负荷早期组0%(IQR 22.8)vs 延迟组0%(IQR 5.6),P=0.45。
- 12个月抗心律失常药物使用率早期组33% vs 延迟组37%,P=0.8。
临床怎么用
- 对于有症状房颤患者,延迟12个月消融以先行优化药物治疗的策略不劣于早期消融,可作为临床决策参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Catheter ablation is an effective strategy in atrial fibrillation (AF). However, its timing in the course of management remains unclear. The aim of this study was to determine if an early vs. delayed AF ablation strategy is associated with differences in arrhythmia outcomes during 12-month follow-up. METHODS AND RESULTS: One hundred patients with symptomatic AF referred to a tertiary centre for management were randomized in a 1:1 ratio to either an early ablation strategy (within 1 month of recruitment) or a delayed ablation strategy (optimized medical therapy followed by catheter ablation at 12 months post recruitment). The primary endpoint was atrial arrhythmia free survival at 12 months post-ablation. Secondary outcomes included: (i) AF burden, (ii) AF burden by AF phenotype, and (iii) antiarrhythmic drug (AAD) use at 12 months. Overall, 89 patients completed the study protocol (Early vs. Delayed: 48 vs. 41). Mean age was 59 ± 12.9 years (29% women). Pulmonary vein isolation was achieved in 100% of patients. At 12 months, 56.3% of patients in the early ablation group were free from recurrent arrhythmia, compared with 58.6% in the delayed ablation group (HR 1.12, 95% CI 0.59-2.13, P = 0.7). All secondary outcomes showed no significant difference including median AF burden (Early vs. Delayed: 0% [IQR 3.2] vs. 0% [5], P = 0.66), median AF burden amongst paroxysmal AF patients (0% [IQR 1.1] vs. 0% [4.5], P = 0.78), or persistent AF patients (0% [IQR 22.8] vs. 0% [5.6], P = 0.45) or AAD use (33% vs. 37%, P = 0.8). CONCLUSION: Compared with an early ablation strategy, delaying AF ablation by 12 months for AAD management did not result in reduced ablation efficacy.
引用
- Kalman JM, Al-Kaisey AM, Parameswaran R, et al. Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences. Eur Heart J. 2023. PMID: 37062010. doi:10.1093/eurheartj/ehad247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。